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A B S T R A C T
Hyperuricemia is becoming a serious public health issue, which is highly influenced by environmental factors,
although there is still controversial information on the potential influence of the exposure to Persistent Toxic
Substances (PTSs) in the general population. In this study we aimed to assess the association. PTS exposure with
uric acid homeostasis in a sample of the Spanish population.
Participants were recruited during 2009–2010 in all the main geographical areas of Spain. Exposure to 34
PTSs was estimated by chemical analyses of serum levels of 6 Polychlorinated Biphenyls (PCBs, n= 950), 13
Organochlorine Pesticides (OCPs, n= 453), 6 Perfluoroalkyl Substances (PFAs, n= 755), 7 Polybrominated
Diphenyl Ethers (PBDEs, n= 365), urinary Cadmium (n= 926), and Lead in whole blood (n= 882). The two
study outcomes were defined as the prevalence of hyperuricemia in the study population and uric acid levels, the
latter only in individuals with no previous diagnosis of hyperuricemia. Statistical analyses were performed by
means of binomial logistic regression and linear regression, and mixture effects were screened using Weighted
Quantile Sum Regression (WQS).
Serum concentrations of γ-HCH, o,p´-DDE, PCB-138, PCB-153, PFOA, and urinary Cadmium were associated
with an increased risk of hyperuricemia, while PBDE-153 showed an inverse association with the effect.
Furthermore, exposure to Cadmium, PCB-138, and to PCB-153 was positively associated with uric acid levels.
Results were consistent after lipid adjustment or standardization. WQS analyses revealed a major contribution of
PCB-153 within the PCB mixture on both the risk of hyperuricemia and uric acid levels. Sensitivity analyses were
performed by adjusting for dietary habits, fasting glucose and estimated glomerular filtration rate.
Overall, we found novel associations between human exposure to mixtures of PTSs and disturbances in uric
acid homeostasis. However, we cannot completely rule out potential residual confounding effect or reversed-
causality related to the cross-sectional design.
1. Introduction
Uric acid (UA) is an end-product of hepatic purine metabolism in
humans (de Oliveira and Burini, 2012), and blood levels are dependent
on the balance between the production (either from dietary purine in-
take or endogenous production) and excretion (renal [65–75%] or
gastrointestinal [25–35%]) (Perez-Ruiz et al., 2002). Failures in renal
excretion account for 90% of the morbidity related to increased UA
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levels (Mandal and Mount, 2015).
Elevated serum UA levels can have pathological implications. In
fact, an estimated 5% of the individuals with UA > 9mg/dL develop
gout, a systemic condition characterized by the deposition of mono-
sodium urate crystals in body tissues, particularly joints (Ragab et al.,
2017). Gout is early manifested in acute joint inflammation, while
medium to long-term manifestations include renal stones and tophi
(Ragab et al., 2017). Of special concern is the apparently close re-
lationship between hyperuricemia and other chronic systemic diseases,
such as hypertension, diabetes mellitus, cardiovascular disease, obesity,
or metabolic syndrome, which are usually presented as bidirectional
comorbidities (Katsiki et al., 2013; Kuo et al., 2015; Mazzali et al.,
2010; Mortada, 2017).
Hyperuricemia figures during recent decades indicate that it is be-
coming increasingly prevalent, particularly in developed countries
(Neogi, 2008). Previous research has identified a number of non-mod-
ifiable risk factors, such as age, sex, ethnicity, and specific genetic
variants that may induce an increased risk of hyperuricemia
(MacFarlane and Kim, 2014). In addition, the important variations in
the prevalence of hyperuricemia according to geographical areas and
sociodemographic characteristics (Song et al., 2018) suggest a relevant
causal role of environmental factors in the pathogenesis.
Virtually all humans are daily exposed to persistent toxic substances
(PTSs), which are highly resistant to the degradation and tend to ac-
cumulate and very often biomagnify along the food chain (Porta et al.,
2003). PTSs include organic molecules, such as Organochlorine Pesti-
cides (OCPs), which have been widely used both in agriculture and
public health interventions; Polychlorinated Biphenyl (PCBs), a wide
group of 209 congeners which have been used in multitude of industrial
applications, e.g., in thermal insulation or as coolants (ATSDR, 2000);
Perfluoroalkyl Substances (PFAs), used in a variety of consumer pro-
ducts and industrial processes, e.g. liquid repellant, industrial surfac-
tants, firefighting foams (Schultz et al., 2003); or Polybrominated Di-
phenyl Ethers (PBDEs), very often present as flame retardants in the
composition of electronics, textiles, building materials, or furnishings,
among others (Fromme et al., 2016). PTSs also include inorganic ele-
ments such as heavy metals, many of them naturally present in the
environment, but also widely used for industrial, agricultural, domestic
and technological purposes (Tchounwou et al., 2012).
Previous epidemiological and experimental research has evidenced
adverse chronic health outcomes linked to long-term human exposure
to low-doses of PTSs (or even mixtures of them), such as OCPs or PFAs
with metabolic syndrome (Lin et al., 2009; Mustieles et al., 2017) and
hypertension (Arrebola et al., 2015); PCBs, PBDEs, or heavy metals with
cardiovascular disease risk (Gump et al., 2014; Ruiz-Hernandez et al.,
2017; Singh and Chan, 2017) or chronic kidney disease (Lunyera and
Smith, 2017). There are some epidemiological evidences supporting a
role of PTS exposure in the development of hyperuricemia and/or gout,
both in accidentally-exposed populations [e.g furans in Japan
(Imamura et al., 2009), PFAs in the United States (Steenland et al.,
2010), PFAs in Italy (Costa et al., 2009), and polychlorinated dibenzo-p-
dioxins and PFAs in Taiwan (Chang et al., 2013; Qin et al., 2016)], as
well as in baseline populations [e.g. lead in China (Dai et al., 2015), or
PFAs, OCPs, Polychlorinated Dibenzo-p-Dioxins, and dioxin-like PCBs in
the United States (Gleason et al., 2015 pp. 2007–2010; Lee et al.,
2013)].
BIOAMBIENT.ES project is encompassed in a Spanish National
Human Biomonitoring program (HBM) (Pérez-Gómez et al., 2013),
which was promoted by the Spanish Ministry of Agriculture, Food and
the Environment. The project aims to enhance the current under-
standing of the distribution of priority PTSs in the Spanish population
and to establish reference values, by analyzing a representative sample
of the Spanish working population (Bartolomé et al., 2015; Cañas et al.,
2014; Huetos et al., 2014; López-Herranz et al., 2016; Ramos et al.,
2017).
The present research aims to expand the current knowledge of the
potential metabolic disrupting effect of PTSs, by examining their asso-
ciations with uric acid homeostasis in the BIOAMBIENT.es population.
2. Methods
2.1. Study population
The present research is based on BIOAMBIENT.ES study, which was
designed to recruit a representative sample of the Spanish workforce.
The study population was recruited between March 2009 and July 2010
among those occupationally active individuals who underwent their
annual medical check-up. An extensive description of the study has
been published elsewhere, including the protocols, recruitment process,
characteristics of the study population, and PTS concentrations (Pérez-
Gómez et al., 2013; Bartolomé et al., 2017; Cañas et al., 2014; Esteban
et al., 2013; Huetos et al., 2014; López-Herranz et al., 2016; Ramos
et al., 2017). Self-administered questionnaires were used to gather in-
formation on socio-demographic, lifestyle and environmental variables,
tobacco exposure, and diet.
Clinical information was gathered from the hospital records and
during the annual occupational medical check-up of each participant.
For the present study, we considered two outcomes:
1. Prevalent hyperuricemia (dichotomous, hyperuricemic/normour-
icemic). A participant was considered hyperuricemic if he/she met
≥1 of the following criteria: a) serum uric acid levels ≥7.0mg/dL
in males or≥ 6.0mg/dL in females, at recruitment or in previous
screenings, b) had been prescribed any pharmacological treatment
for lowering uric acid levels, and/or c) had been diagnosed with
gout by a clinician.
2. Serum uric acid levels (interval, mg/dL) in the analyses at recruit-
ment.
From the 1880 individuals that provided biological samples, 950
(50.5%) had clinical information on diagnosis of hyperuricemia in their
records. From these, a total of 134 had been diagnosed with hyperur-
icemia, which means a prevalence of 14.1%. Serum uric acid analyses at
recruitment was available from all the mentioned 950 individuals.
2.2. Ethical approval
The study was performed in accordance with legal/ethical princi-
ples and regulations concerning research involving individual in-
formation and biological samples, including “Organic Law 15/1999 on
Personal Data protection and its Regulations”, “Law 41/2002, on
Autonomy of Patients and rights and obligations relating to health in-
formation and documentation”, “General Health Law 14/1986”,
Declaration of Helsinki, and UNESCO Universal Declaration on the
Human Genome and Human Rights. The study protocol was approved
by Comité Ético Científico and the Legal Department of IBERMUTUA-
MUR.
2.3. Sample preparation and chemical analysis of persistent pollutants
Exposure to selected PTSs was estimated from chemical analyses of
their concentrations in serum, blood or urine. Protocols of sample
preparation, chemical analyses, and quality control have been pre-
viously described (Bartolomé et al., 2017; Cañas et al., 2014; Esteban
et al., 2013; Huetos et al., 2014; López-Herranz et al., 2016; Ramos
et al., 2017).
A total of 34 PTSs were included in this study: serum poly-
brominated diphenyl ethers (PBDEs, congeners −28, −47, −99,
−100, −153, −154, −183), serum perfluorinated alkyl substances
(PFAs, perfluoroctane sulfonate [PFOS]; perfluorooctanoic acid
[PFOA]; perfluorohexane sulfonate [PFHxS]; perfluorononanoic acid
[PFNA]; perfluorodecanoic acid [PFDA]; N-Methylperfluorooctane
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Sulfonamide [N-MeFOSAA]), serum organochlorine pesticides p,p´- and
o,p´-DDE; p,p´- and o,p´-DDT; aldrin; dieldrin; endrin; hexa-
chlorobenzene [HCB]; heptachlor; heptachlor epoxide; α-, β-, and γ-
hexachlorocyclohexane [α-, β-, and γ-HCH]); and Polychlorinated
Biphenyls (PCBs, congeners −28, −52, −101, −138, −153, −180),
urinary Cadmium (Cd), and Lead in whole blood (Pb). Chemical ana-
lyses of the 34 PTSs were performed between 2010 and 2017, although
each family was analyzed during a maximum period of 8months.
Total cholesterol and triglycerides were quantified in serum samples
by means of an enzymatic method coupled to spectrophotometry at
500 nm (Bernert et al., 2007), and total serum lipids were estimated as
described elsewhere (Phillips et al., 1989). Urinary creatinine was
analyzed by Jaffé method using a commercial kit (Spinreact, Spain).
Estimated Glomerular filtration rate was calculated using CDK-EPI
(Chronic Kidney Disease Epidemiology Collaboration) formula (Levey
et al., 2009)
From the 1880 recruited individuals, clinical information was
available from 950. PCBs were analyzed in all the 950 individuals,
while a subset of 453 was screened for OCPs, 755 for PFAs, 925 for Cd,
and 882 for Pb.
2.4. Statistical analysis
First, associations between individual PTS concentrations and hy-
peruricemia were studied by binomial unconditional logistic regression,
calculating odds ratios (ORs) with their corresponding 95% confidence
intervals (CIs). PTS concentrations were entered as log-transformed
variables when their levels of quantification were > 60%, or as di-
chotomous variables (> LOQ vs < LOQ) in those PTS with levels of
quantification<60%. When PTS concentrations were used as con-
tinuous variables, concentrations below the limit of quantification
(LOQ) were replaced by the LOQ divided by the square root of two.
Chemicals with no sample > LOD (i.e. α-HCH, Heptachlor, Aldrin,
Endrin, and o,p´-DDT) were not considered in any of the multivariable
analyses.
As a measure of a potential cumulative effect, we explored the risk
of hyperuricemia in those individuals with the highest number of
chemicals at increased concentrations. For this purpose, we selected
those chemicals significantly associated with hyperuricemia in the in-
dividual models and considered that a study participant was highly
exposed to a specific PTS when he/she showed concentrations in the
4th quartile (for PTSs with quantification levels> 25%) or > LOQ (for
PTSs with quantification levels< 25%). Then, the total number of PTSs
at high concentrations was calculated in each participant and categor-
ized as a dichotomous variable (≥2/<2 PTSs), and its association
with the risk of hyperuricemia assessed by unconditional logistic re-
gression. These analyses were restricted to the 92 individuals who had
been analyzed for the five PTS families of interest.
The linear regression analyses of the associations between PTS
concentrations and uric acid levels were carried out without the 134
individuals previously diagnosed with hyperuricemia, given that the
receipt of medical intervention might have artificially modified their
uric acid levels. The shape of the associations were assessed by using
locally weighted scatterplot smoothing (LOWESS) and Generalized
Additive Models (GAM), and further analyses were performed by means
of multivariable linear regression.
All the logistic and linear regression models were adjusted for
variables whose inclusion in any model produced changes> 10% in
beta coefficients and/or those reported as potential confounders in
previous studies, i.e., sex (male/female), age (yrs), body mass index
(kg/m2), weight loss during the previous 6months (< 1 Kg/1–5 Kg/
≥6 Kg), region of residence (North, Center, East, South), smoking habit
(non-smoker/smoker/former smoker), alcohol consumption (non-con-
sumer/consumer), and education (primary or lower/secondary/uni-
versity).
In order to assess the robustness of our findings, four sensitivity
analyses were performed. Given that certain dietary habits are con-
sidered a risk factor for hyperuricemia, but can also be a source of PTS
exposure in the general population, we re-built the models adjusting for
self-reported habitual consumption of the following items: fruit, meat,
eggs, fish, pasta/rice/potatoes, bread, vegetables, legumes, cold cuts,
dairy products, and sweets (e.g. biscuits, cakes). Food consumption was
categorized in 5 levels: ≤1/week, 1/week, 2–4/ week, 5–6/week, ≥1/
day, and entered in each model using a forward stepwise technique
based on changes in Akaike information criterion (AIC). Models were
also adjusted for fasting glucose and estimated glomerular filtration
rate, given the existing evidences supporting that elevated uric acid
levels might be a consequence of a decreased renal function and/or
insulin resistance (Li et al., 2013; Prasad Sah and Qing, 2015). Fur-
thermore, and considering that serum lipids may be associated with the
underlying metabolic perturbation of participants as well as influence
the concentrations of the most lipophilic families (e.g. OCPs, PCBs, and
PBDEs), we also performed the multivariable models using wet-basis
concentrations of these families, with and without adjustment by total
serum lipids (Tables 3 and 4). Additionally, the models were repeated
after removing individuals with diagnosis of diabetes, hypertension
and/or renal disease (data not shown in tables but mentioned in the
results section).
The potential mixture effect within the different PTS families was
assessed using Weighted Quantile Sum Regression (WQS, Carrico et al.,
2015), which combines the individual associations into a weighted
index, and estimates the specific weight of each chemical on the mix-
ture. Associations between each WQS index and its corresponding
outcome were further studied by using multivariable linear or logistic
regression, when appropriate, adjusting for the same covariates in-
cluded in the individual models. Given the different sample size of each
family of pollutants, we performed WQS index calculation on each in-
dividual family, and therefore the individual contribution of each
chemical reflects its relative effect within its family. In addition, we also
performed WQS analyses entering all the chemicals positively asso-
ciated with the effects in the multivariable models, although these re-
sults should be taken with care given the limited number of individuals.
Each WQS model was calculated by entering the chemicals of the same
family with ≥60% samples> LOQ. The WQS analyses were performed
with quartile-scored pollutant concentrations, using a training set de-
fined as a 40% random sample of the dataset, being the remaining 60%
used for model validation. The final weights were calculated using a
total of 400 bootstrap steps.
The statistical significance level was set at p=0.05, although p-
values< 0.10 were considered as marginally-significant. R statistical
computing environment v3.4.0 (http://www.r-project.org/) was used
for data analyses, with gWQS package v1.0.0 for the calculations of
WQS index.
3. Results
Table 1 summarizes the main sociodemographic, anthropometric,
clinical and lifestyle characteristics of each population subsample in
which each group of PTSs was analyzed. Median age ranged from 35.4
to 38.1 years. There was a similar proportion of males and females, with
the exception of the subsample included in the OCP analyses, that
showed a higher proportion of males than females (68% vs 32%, re-
spectively). The population had predominantly secondary studies
(57%–61%) and the majority of the participants were recruited in the
central area of the country (38.4% - 40.4%). Median (25th–75th per-
centiles) uric acid levels were 3.6 mg/dL (4.8–5.9), and there were 134
(14%) of individuals with hyperuricemia. These characteristics did not
substantially differ when restricting the analyses to normouricemic
individuals (Supplemental Material, Table S1). Total serum lipids were
positively and significantly associated with both the risk of hyperur-
icemia (OR=1.25, p=0.001) and uric acid levels (beta= 0.03,
p=0.001), the latter only in normouricemic individuals.
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A description of PTS concentrations in the study population is dis-
played in Table 2. We did not find substantial differences in the con-
centrations when only individuals with no hyperuricemia were selected
(Supplemental Material, Table S2). PTS levels and predictors have been
extensively discussed elsewhere (Bartolomé et al., 2017; Cañas et al.,
2014; Huetos et al., 2014; López-Herranz et al., 2016; Ramos et al.,
2017).
The results of the multivariable logistic regression analyses between
individual PTS levels and the risk of hyperuricemia in the study po-
pulation are shown in Table 3. Serum concentrations of PCB-138, PCB-
153, PCB-180, PFOA, as well as urinary Cadmium were associated with
an increased risk of hyperuricemia, while PBDE-153 showed an inverse
association with the risk. Furthermore, participants with γ-HCH and
o,p´-DDE concentrations> LOQ also showed a marginally-significant
increased risk (in comparison to those with concentrations< LOQ). The
observed associations did not substantially change after adjustment for
total serum lipids or when the concentrations of the most lipophilic
chemicals were expressed on a lipid basis (Table 3). Adjustments for
dietary items only produced relevant changes in the estimates for
PFOA, in which the magnitude of the association decreased (Supple-
mentary Material, Table S3), but after adjustment for CDK-EPI and
fasting glucose (Supplementary Material, Table S3). However, new
significant associations emerged after adjustment for dietary items or
fasting glucose and urinary creatinine, with PBDE-100 and PCB-180
being positively associated with the risk of hyperuricemia (Supple-
mental Material, Table S3). Stratification by sex or deletion of in-
dividuals with diagnosis of diabetes, cardiovascular disease and/or
hypertension did not substantially affect the results (data not shown).
From the 92 individuals that had available analyses of the three
groups of PTSs (PCBs, organochlorine pesticides, and PFAs), a total of
37 (40.3%) had increased levels of ≥2 of the PTSs individually asso-
ciated with the risk of hyperuricemia (i.e., PFOA, PFNA, γ-HCH, PCB-
101, PCB-138, PCB-153 and/or PCB-180). These participants showed a
higher risk of developing hyperuricemia, but the association was only
marginally significant, probably due to the limited sample size
(OR=1.70, p=0.066) (data not shown in tables).
Table 4 shows the results from the multivariable linear regression
analyses between PTS concentrations and serum uric acid levels in
normouricemic individuals. These analyses were restricted to those
participants without diagnosed hyperuricemia because the treatment of
the disease will likely modify the levels of uric acid. Serum con-
centrations of PCB-138 and PCB-153, as well as urinary Cadmium,
showed positive associations with uric acid levels, while PBDE-153 was
inversely associated with uric acid. The observed associations did not
substantially change when the concentrations of the most lipophilic
chemicals were expressed on a lipid-basis or after adjustment for total
serum lipids (Table 4). Adjustment for dietary items did not produce
relevant changes in the models, but new associations emerged after
adjustment for CDK-EPI and fasting glucose, with PFHxS, PFOA, and
HCB being also positively associated with uric acid levels (Supple-
mental Material, Table S4). No relevant differences were observed after
stratification by sex (Data not shown in tables).
As explained above, given the different sample size of each family of
PTSs, we calculated a WQS index for each of the three families, and
Table 1
Characteristics of the study population according to the groups of PTSs analyzed.
PBDEs (n= 365) PFAs (n=342) OCPs (n= 453) PCBs (n=950) Cd (n=925) Pb (n= 882)
n % n % n % n % n % n %
Sex
Male 195 53.4 164 48.0 308 68.0 497 52.3 482 52.1 458 51.9
Female 170 46.6 178 52.0 145 32.0 453 47.7 443 47.9 424 48.1
Education
Primary or lower 44 12.1 54 15.8 57 12.6 121 12.7 118 12.8 109 12.4
Secondary 221 60.5 195 57.0 278 61.4 574 60.4 558 60.3 528 59.9
University 100 27.4 93 27.2 118 26.0 255 26.8 249 26.9 245 27.8
Region of recruitment
North 111 30.4 92 26.9 118 26.1 252 26.5 244 26.4 235 26.6
North-East 7 1.9 9 2.6 5 1.1 16 1.7 16 1.7 16 1.8
Center 142 38.9 138 40.4 175 38.6 365 38.4 362 39.1 343 38.9
East 53 14.5 55 16.1 74 16.3 166 17.5 163 17.6 154 17.5
South 59 16.2 57 16.7 86 19.0 167 17.6 156 16.9 150 17.0
Smoking habit
Non-smoker 204 55.9 205 59.9 260 57.4 538 56.6 524 56.6 503 57.0
Smoker 149 40.8 129 37.7 178 39.3 384 40.4 373 40.3 352 39.9
Former smoker 12 3.3 8 2.3 15 3.3 28 2.9 28 3.0 27 3.1
Alcohol consumption
Non-consumer 43 11.8 34 9.9 42 9.3 99 10.4 93 10.1 87 9.9
Consumer 322 88.2 308 90.1 411 90.7 851 89.6 832 89.9 795 90.1
Weight loss during last 6 months
<1 Kg 272 74.5 274 80.1 344 75.9 736 77.5 713 77.1 675 76.5
1–5 Kg 67 18.4 55 16.1 77 17.0 158 16.6 156 16.9 152 17.2
≥6 Kg 26 7.1 13 3.8 32 7.1 56 5.9 56 6.1 55 6.2
Place of residence
City center 267 74.2 244 71.8 322 71.6 672 71.6 658 71.8 627 71.7
Other 93 25.8 96 28.2 128 28.4 266 28.4 259 28.2 247 28.3
Percentiles Percentiles Percentiles Percentiles Percentiles Percentiles
25th 50th 75th 25th 50th 75th 25th 50th 75th 25th 50th 75th 25th 50th 75th 25th 50th 75th
Age (yrs) 31.0 37.4 44.9 31.7 38.1 46.1 30.4 35.4 41.7 31.0 37.4 44.3 31.0 37.4 44.3 30.9 37.1 44.0
Abdominal perimeter (cm) 78.0 87.0 94.0 77.0 86.0 95.0 80.0 87.0 95.0 78.0 86.0 95.0 78.0 86.0 95.0 78.0 86.0 95.0
Body Mass Index (Kg/m2) 23.1 25.3 28.0 22.5 25.2 28.1 23.3 25.4 27.9 22.9 25.2 28.0 22.9 25.2 28.0 22.9 25.2 28.0
Total serum lipids (g/L) 5.1 5.9 6.6 5.1 5.9 6.8 5.1 5.8 6.6 5.1 5.8 6.6 5.1 5.8 6.6 5.1 5.8 6.6
Uric acid (mg/dL) 3.6 4.8 5.9 3.6 4.5 5.9 4.0 5.1 6.1 3.6 4.7 6.0 3.6 4.7 6.0 3.6 4.7 6.0
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therefore the contribution of each chemical reflects its relative effect
within its family. WQS index for PCBs was positively and borderline-
significantly associated with both the risk of hyperuricemia (exp
[beta]= 2.02; p < 0.001) and uric acid concentrations (beta= 0.43;
p=0.01). PCB -153 concentrations accounted for the majority of the
mixture effect in the two models (44% in the model for hyperuricemia
and 59% in the model for uric acid levels) (Fig. 1). With the rest of
families, we did not achieved any index significantly associated with
the effects, although they did not produce any significant results with
the WQS indices, neither in the logistic regression (exp[beta]= 1.75;
p=0.475) nor in the linear regression (beta= 0.62; p= 0.690),
probably because of the limited number of individuals with available
chemical analyses, that restricted the models to n=174 and n=173,
respectively (Data not shown in tables/figures).
4. Discussion
In this article we present novel results suggesting a potential role of
human exposure to mixtures of PTSs on the pathogenesis of hyperur-
icemia. We found not only associations of exposure levels with the risk
of diagnosed hyperuricemia, but also with subclinical uric acid levels.
To the best of our knowledge, our findings of epidemiological as-
sociations of PCBs −138 and−153 with uric acid homeostasis have
not been previously reported, although some effects have been evi-
denced in animals treated with mixtures of PCBs (Burgin et al., 2001;
Kutlu et al., 2007). Regarding metal exposure, cadmium showed par-
ticularly consistent positive associations through all the levels of ad-
justment, both with hyperuricemia and uric acid levels. In this regard,
Sun et al. also reported positive associations of Cd blood levels with uric
acid levels in a Chinese population, which also appeared to be in-
dependent of eGFR (Sun et al., 2017). Furthermore, Dai et al. (2015)
reported a positive cross-sectional association between blood Pb levels
and the risk of hyperuricemia in China. However, Sponder et al. (2014)
did not find significant associations between biomarkers of Cd and Pb
exposure with uric acid levels in 164 patients with coronary artery
disease from Austria. Steenland et al. (2010) reported significant cross-
sectional positive associations of PFOA and PFOS exposure with hy-
peruricemia in a highly-exposed US population, which were in line with
those from Geiger et al. (2013) and Shankar et al. (2011) using
NHANES data. Also in the NHANES population, serum OCPs, PCDDDs,
and dioxin-like PCBs (but not non-dioxin-like PCBs) were positively
associated with the risk of hyperuricemia (Lee et al., 2013).
The negative coefficients for all PDBEs in the multivariable models
for hyperuricemia and uric acid levels (which were statistically sig-
nificant for congener −153) were unexpected and warrant further re-
search. To the best of our knowledge, these associations have not been
previously reported at an epidemiological level. In experimental stu-
dies, Ernest et al. found a marginally-significant reduction in uric acid
levels with increasing exposure doses of brominated flame retardants in
adult male rates (Ernest et al., 2012)), although Van den Steen et al. did
not observed significant differences between exposed and non-exposed
European starlings (Van den Steen et al., 2010)
Humans are typically exposed to complex mixtures of potentially
metabolic-disrupting environmental pollutants, which represent an
important issue in the risk assessment process. Relevant mixture effects
can be observed even when the single concentrations are below their
safety levels (Kortenkamp, 2014), and variations in the concentrations
of one chemical might even alter the bioavailability of the others
Table 2
PTS concentrations the study population.
Units Percentiles
5th 10th 25th 50th 75th 90th 95th
PBDE-28 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ 0.07 0.13 0.19
PBDE-47 (ng/g lipid) < LOQ <LOQ <LOQ 0.06 0.29 0.80 1.41
PBDE 99 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ 0.19 0.30
PBDE-100 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ 0.15 0.31 0.52
PBDE-153 (ng/g lipid) 0.15 0.21 0.32 0.47 0.71 1.10 1.55
PBDE-154 (ng/g lipid) 0.06 0.06 0.08 0.15 0.26 0.40 0.50
PBDE-183 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ 0.13 0.25
PFHxS (ng/mL) < LOQ <LOQ 0.45 0.73 1.07 1.50 2.04
PFOA (ng/mL) 0.82 1.03 1.34 1.83 2.53 3.44 4.32
PFOS (ng/mL) 2.35 3.21 5.14 7.23 10.11 14.03 17.76
PFNA (ng/mL) 0.44 0.50 0.64 0.88 1.26 1.69 1.91
PFDA (ng/mL) 0.14 0.14 0.24 0.35 0.54 0.76 0.99
N-Me-FOSA (ng/mL) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
HCB (ng/g lipid) < LOQ 6.50 14.09 28.09 56.49 114.40 207.99
α-HCH (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
β-HCH (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ 0.07 0.12
γ-HCH (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ 0.03 0.05
Heptachlor (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Heptachlor epoxide (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0.01
Aldrin (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Endrin (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
Dieldrin (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ 0.02 0.02
p,p´-DDE (ng/g lipid) 31.59 45.75 83.10 152.50 280.34 519.44 696.63
o,p´-DDE (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
p,p´-DDT (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ 5.80 9.40
o,p´-DDT (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PCB-28 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PCB-52 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ
PCB-101 (ng/g lipid) < LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 51.37
PCB-138 (ng/g lipid) 5.37 9.59 19.01 34.45 56.25 84.54 109.64
PCB-153 (ng/g lipid) 7.03 13.83 24.80 45.14 74.24 112.49 149.25
PCB-180 (ng/g lipid) 10.17 18.63 30.73 58.30 96.51 156.39 194.63
Cadmium (ng/mL) < LOQ <LOQ 0.17 0.27 0.48 0.77 0.99
Lead (ng/mL) 0.11 0.31 0.63 1.06 1.81 2.84 3.55
LOQ: Limit of quantification.
J.P. Arrebola et al. Environment International 123 (2019) 512–521
516
Ta
bl
e3
PT
Sc
on
ce
nt
rat
ion
sa
nd
ris
ko
fh
yp
eru
ric
em
ia.
Lo
gis
tic
reg
res
sio
nm
od
els
wi
th
ind
ivi
du
al
po
llu
tan
ts.
W
et-
ba
sis
mo
de
ls
Lip
id-
ba
sis
mo
de
ls
W
et
ba
sis
mo
de
ls+
ad
jus
tm
en
tf
or
ser
um
lip
ids
Un
its
OR
95
%
CI
p-V
alu
e
Un
its
OR
95
%
CI
p-V
alu
e
Un
its
OR
95
%
CI
p-V
alu
e
low
er
up
pe
r
low
er
up
pe
r
low
er
up
pe
r
PB
DE
-28
(≥
LO
Q
vs
<
LO
Q)
0.8
8
0.4
1
1.8
1
0.7
27
(≥
LO
Q
vs
<
LO
Q)
0.8
8
0.4
1
1.8
1
0.7
27
(≥
LO
Q
vs
<
LO
Q)
0.8
8
0.4
1
1.8
1
0.7
24
PB
DE
-47
(≥
LO
Q
vs
<
LO
Q)
0.7
4
0.3
6
1.5
1
0.4
13
(≥
LO
Q
vs
<
LO
Q)
0.7
4
0.3
6
1.5
1
0.4
13
(≥
LO
Q
vs
<
LO
Q)
0.7
4
0.3
6
1.5
1
0.4
09
PB
DE
-10
0
(≥
LO
Q
vs
<
LO
Q)
0.5
6
0.2
6
1.1
6
0.1
24
(≥
LO
Q
vs
<
LO
Q)
0.5
6
0.2
6
1.1
6
0.1
24
(≥
LO
Q
vs
<
LO
Q)
0.5
6
0.2
6
1.1
6
0.1
23
PB
DE
99
(≥
LO
Q
vs
<
LO
Q)
0.7
9
0.3
2
1.8
4
0.6
02
(≥
LO
Q
vs
<
LO
Q)
0.7
9
0.3
2
1.8
4
0.6
02
(≥
LO
Q
vs
<
LO
Q)
0.7
7
0.3
1
1.8
0
0.5
65
PB
DE
-15
4
(n
g/
mL
)
0.7
3
0.4
1
1.2
6
0.2
80
(n
g/
gl
ipi
d)
0.9
3
0.5
5
1.4
9
0.7
82
(n
g/
mL
)
0.7
0
0.3
8
1.2
3
0.2
34
PB
DE
-15
3
(n
g/
mL
)
0.5
2
0.3
0
0.8
6
0.0
12
(n
g/
gl
ipi
d)
0.4
9
0.2
8
0.8
3
0.0
09
(n
g/
mL
)
0.5
0
0.2
9
0.8
3
0.0
09
PB
DE
-18
3
(≥
LO
Q
vs
<
LO
Q)
1.3
6
0.7
7
2.2
8
0.2
66
(≥
LO
Q
vs
<
LO
Q)
1.3
2
0.7
5
2.2
2
0.3
14
(≥
LO
Q
vs
<
LO
Q)
1.3
5
0.7
6
2.2
8
0.2
78
PF
Hx
S
(n
g/
mL
)
1.3
6
0.7
2
2.5
8
0.3
37
(n
g/
mL
)
1.3
6
0.7
2
2.5
8
0.3
37
(n
g/
mL
)
1.3
3
0.7
0
2.5
4
0.3
77
PF
OA
(n
g/
mL
)
1.8
3
0.9
3
3.6
8
0.0
83
(n
g/
mL
)
1.8
3
0.9
3
3.6
8
0.0
83
(n
g/
mL
)
1.7
8
0.9
0
3.4
5
0.0
95
PF
OS
(n
g/
mL
)
1.7
0
0.8
6
3.4
9
0.1
38
(n
g/
mL
)
1.7
0
0.8
6
3.4
9
0.1
38
(n
g/
mL
)
1.6
7
0.8
4
3.4
1
0.1
51
PF
NA
(n
g/
mL
)
1.6
8
0.8
0
3.6
1
0.1
76
(n
g/
mL
)
1.6
8
0.8
0
3.6
1
0.1
76
(n
g/
mL
)
1.6
8
0.8
0
3.6
1
0.1
76
PF
DA
(n
g/
mL
)
1.0
1
0.5
2
1.9
7
0.9
67
(n
g/
mL
)
1.0
1
0.5
2
1.9
7
0.9
67
(n
g/
mL
)
1.0
0
0.5
1
1.9
4
0.9
98
N-
Me
-FO
SA
(≥
LO
Q
vs
<
LO
Q)
0.4
9
0.0
3
3.3
9
0.5
22
(≥
LO
Q
vs
<
LO
Q)
0.4
9
0.0
3
3.3
9
0.5
22
(≥
LO
Q
vs
<
LO
Q)
0.5
0
0.0
3
3.4
6
0.5
31
HC
B
(n
g/
mL
)
1.1
2
0.7
7
1.6
6
0.5
46
(n
g/
gl
ipi
d)
1.1
2
0.7
6
1.6
5
0.5
64
(n
g/
mL
)
1.1
2
0.7
6
1.6
6
0.5
54
β-
HC
H
(≥
LO
Q
vs
<
LO
Q)
1.1
6
0.5
3
2.4
0
0.6
99
(≥
LO
Q
vs
<
LO
Q)
1.1
6
0.5
3
2.4
0
0.6
99
(≥
LO
Q
vs
<
LO
Q)
1.1
6
0.5
3
2.4
1
0.6
94
γ-H
CH
(≥
LO
Q
vs
<
LO
Q)
1.8
5
0.9
0
3.6
9
0.0
86
(≥
LO
Q
vs
<
LO
Q)
1.8
5
0.9
0
3.6
9
0.0
86
(≥
LO
Q
vs
<
LO
Q)
1.7
8
0.8
7
3.5
8
0.1
09
He
pta
ch
lor
ep
ox
ide
(≥
LO
Q
vs
<
LO
Q)
1.6
6
0.6
3
4.0
8
0.2
87
(≥
LO
Q
vs
<
LO
Q)
1.6
6
0.6
3
4.0
8
0.2
87
(≥
LO
Q
vs
<
LO
Q)
1.5
9
0.6
0
3.9
3
0.3
26
Di
eld
rin
(≥
LO
Q
vs
<
LO
Q)
1.0
5
0.5
0
2.0
9
0.8
98
(≥
LO
Q
vs
<
LO
Q)
1.0
5
0.5
0
2.0
9
0.8
98
(≥
LO
Q
vs
<
LO
Q)
1.1
0
0.5
3
2.2
0
0.7
96
p,p
´-D
DE
(n
g/
mL
)
1.3
0
0.9
5
1.7
9
0.1
03
(n
g/
gl
ipi
d)
1.2
7
0.9
2
1.7
5
0.1
44
(n
g/
mL
)
1.2
7
0.9
3
1.7
5
0.1
43
o,p
´-D
DE
(≥
LO
Q
vs
<
LO
Q)
2.7
3
0.7
7
8.5
9
0.0
96
(≥
LO
Q
vs
<
LO
Q)
2.7
3
0.7
7
8.5
9
0.0
96
(≥
LO
Q
vs
<
LO
Q)
2.6
6
0.7
5
8.3
9
0.1
06
p,p
´-D
DT
(≥
LO
Q
vs
<
LO
Q)
1.3
0
0.4
5
3.5
8
0.6
20
(≥
LO
Q
vs
<
LO
Q)
1.3
0
0.4
5
3.5
8
0.6
20
(≥
LO
Q
vs
<
LO
Q)
1.2
6
0.3
8
3.9
2
0.7
00
PC
B-
28
(≥
LO
Q
vs
<
LO
Q)
2.4
5
0.1
2
19
.46
0.4
51
(≥
LO
Q
vs
<
LO
Q)
2.4
5
0.1
2
19
.46
0.4
51
(≥
LO
Q
vs
<
LO
Q)
2.3
6
0.1
1
18
.74
0.4
73
PC
B-
52
(≥
LO
Q
vs
<
LO
Q)
1.6
3
0.2
4
6.5
7
0.5
42
(≥
LO
Q
vs
<
LO
Q)
1.6
3
0.2
4
6.5
7
0.5
42
(≥
LO
Q
vs
<
LO
Q)
1.4
9
0.2
2
6.0
3
0.6
21
PC
B-
10
1
(≥
LO
Q
vs
<
LO
Q)
1.2
4
0.6
0
2.4
3
0.5
50
(≥
LO
Q
vs
<
LO
Q)
1.2
4
0.6
0
2.4
3
0.5
50
(≥
LO
Q
vs
<
LO
Q)
1.2
2
0.5
9
2.3
9
0.5
80
PC
B-
13
8
(n
g/
mL
)
1.4
0
1.0
9
1.8
3
0.0
12
(n
g/
gl
ipi
d)
1.3
2
1.0
3
1.7
4
0.0
36
(n
g/
mL
)
1.3
2
3
1.7
4
0.0
33
PC
B-
15
3
(n
g/
mL
)
1.4
3
1.1
0
1.9
1
0.0
09
(n
g/
gl
ipi
d)
1.3
5
1.0
4
1.8
0
0.0
32
(n
g/
mL
)
1.3
5
1.0
4
1.8
0
0.0
30
PC
B-
18
0
(n
g/
mL
)
1.3
4
1.0
2
1.7
9
0.0
39
(n
g/
gl
ipi
d)
1.2
5
0.9
6
1.6
8
0.1
14
(n
g/
mL
)
1.2
7
0.9
7
1.6
9
0.0
9
Ca
dm
ium
(n
g/
mL
)
1.4
0
1.0
6
1.8
7
0.0
19
(n
g/
mL
)
1.4
0
1.0
6
1.8
7
0.0
19
(n
g/
mL
)
1.3
5
1.0
2
1.8
0
0.0
36
Le
ad
(n
g/
mL
)
1.1
2
0.9
0
1.4
2
0.3
13
(n
g/
mL
)
1.1
2
0.9
0
1.4
2
0.3
13
(n
g/
mL
)
1.1
2
0.9
0
1.4
1
0.3
29
CI
:c
on
fid
en
ce
int
erv
al;
Po
llu
tan
tc
on
ce
nt
rat
ion
sw
ere
log
-tr
an
sfo
rm
ed
;O
R:
Od
ds
Ra
tio
.
Mo
de
ls
we
re
ad
jus
ted
for
sex
(m
ale
/fe
ma
le)
,a
ge
(y
rs)
,b
od
ym
as
si
nd
ex
(k
g/
m2
),
we
igh
tl
os
sd
ur
ing
th
el
as
t6
mo
nt
hs
(<
1K
g/
1–
5K
g/
≥
6K
g),
reg
ion
of
rec
ru
itm
en
t(
No
rth
,C
en
ter
,E
as
t,
So
ut
h)
,s
mo
kin
gh
ab
it
(n
on
-
sm
ok
er/
sm
ok
er/
for
me
rs
mo
ke
r),
alc
oh
ol
co
ns
um
pti
on
(n
on
-co
ns
um
er/
co
ns
um
er)
,e
du
ca
tio
n
(p
rim
ary
or
low
er/
sec
on
da
ry
/u
niv
ers
ity
);
pla
ce
of
res
ide
nc
e(
cit
yc
en
ter
/o
th
er)
.
J.P. Arrebola et al. Environment International 123 (2019) 512–521
517
Ta
bl
e4
PT
Sc
on
ce
nt
rat
ion
sa
nd
ser
um
ur
ic
ac
id
lev
els
(m
g/
dL
)i
n
ind
ivi
du
als
wi
th
no
pr
ev
iou
sd
iag
no
sis
of
hy
pe
ru
ric
em
ia.
Lin
ea
rr
eg
res
sio
nm
od
els
.
W
et-
ba
sis
mo
de
ls
Lip
id-
ba
sis
mo
de
ls
W
et
ba
sis
mo
de
ls+
ad
jus
tm
en
tf
or
ser
um
lip
ids
Un
its
be
ta
95
%
CI
p-V
alu
e
Un
its
be
ta
95
%
CI
p-V
alu
e
Un
its
be
ta
95
%
CI
p-V
alu
e
low
er
up
pe
r
low
er
up
pe
r
low
er
up
pe
r
PB
DE
-28
(≥
LO
Q
vs
<
LO
Q)
−
0.0
7
−
0.1
8
0.0
4
0.2
02
(≥
LO
Q
vs
<
LO
Q)
−
0.0
7
−
0.1
8
0.0
4
0.2
02
(≥
LO
Q
vs
<
LO
Q)
−
0.0
7
−
0.1
8
0.0
4
0.2
05
PB
DE
-47
(≥
LO
Q
vs
<
LO
Q)
0.0
0
−
0.1
0
0.1
0
0.9
77
(≥
LO
Q
vs
<
LO
Q)
0.0
0
−
0.1
0
0.1
0
0.9
77
(≥
LO
Q
vs
<
LO
Q)
0.0
0
−
0.1
0
0.1
0
0.9
81
PB
DE
-10
0
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.1
6
0.0
5
0.3
16
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.1
6
0.0
5
0.3
16
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.1
6
0.0
5
0.3
13
PB
DE
-99
(≥
LO
Q
vs
<
LO
Q)
−
0.0
2
−
0.1
4
0.1
1
0.7
99
(≥
LO
Q
vs
<
LO
Q)
−
0.0
2
−
0.1
4
0.1
1
0.7
99
(≥
LO
Q
vs
<
LO
Q)
−
0.0
2
−
0.1
4
0.1
1
0.7
81
PB
DE
-15
4
(n
g/
mL
)
0.4
1
−
0.7
1
1.5
3
0.4
69
(n
g/
gl
ipi
d)
0.4
5
−
0.6
4
1.5
4
0.4
23
(n
g/
mL
)
0.4
2
−
0.7
4
1.5
7
0.4
80
PB
DE
-15
3
(n
g/
mL
)
−
0.0
8
−
0.1
5
−
0.0
1
0.0
23
(n
g/
gl
ipi
d)
−
0.0
9
−
0.1
6
−
0.0
2
0.0
17
(n
g/
mL
)
−
0.0
9
−
0.1
6
−
0.0
2
0.0
18
PB
DE
-18
3
(≥
LO
Q
vs
<
LO
Q)
0.0
0
−
0.0
9
0.1
0
0.9
18
(≥
LO
Q
vs
<
LO
Q)
0.0
0
−
0.0
9
0.0
9
0.9
75
(≥
LO
Q
vs
<
LO
Q)
0.0
0
−
0.0
9
0.1
0
0.9
48
PF
Hx
S
(n
g/
mL
)
0.0
5
−
0.0
4
0.1
5
0.2
70
(n
g/
mL
)
0.0
5
−
0.0
4
0.1
5
0.2
70
(n
g/
mL
)
0.0
5
−
0.0
4
0.1
5
0.2
71
PF
OA
(n
g/
mL
)
0.0
4
−
0.0
6
0.1
4
0.4
25
(n
g/
mL
)
0.0
4
−
0.0
6
0.1
4
0.4
25
(n
g/
mL
)
0.0
4
−
0.0
6
0.1
4
0.4
59
PF
OS
(n
g/
mL
)
0.0
6
−
0.0
3
0.1
58
0.1
92
(n
g/
mL
)
0.0
6
−
0.0
3
0.1
6
0.1
92
(n
g/
mL
)
0.0
6
−
0.0
3
0.1
57
0.2
07
PF
NA
(n
g/
mL
)
0.0
4
−
0.0
7
0.1
45
0.5
25
(n
g/
mL
)
0.0
4
−
0.0
7
0.1
5
0.5
25
(n
g/
mL
)
0.0
4
−
0.0
7
0.1
45
0.5
25
PF
DA
(n
g/
mL
)
0.0
1
−
0.0
8
0.1
1
0.7
77
(n
g/
mL
)
0.0
1
−
0.0
8
0.1
1
0.7
77
(n
g/
mL
)
0.0
1
−
0.0
8
0.1
1
0.8
04
N-
Me
-FO
SA
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.3
5
0.2
4
0.7
27
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.3
5
0.2
4
0.7
27
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.3
5
0.2
4
0.7
37
HC
B
(n
g/
mL
)
0.0
4
−
0.0
2
0.1
0
0.2
30
(n
g/
gl
ipi
d)
0.0
4
−
0.0
2
0.1
0
0.2
07
(n
g/
mL
)
0.0
4
−
0.0
2
0.1
0
0.2
15
β-
HC
H
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.1
7
0.0
7
0.4
48
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.1
7
0.0
7
0.4
48
(≥
LO
Q
vs
<
LO
Q)
−
0.0
5
−
0.1
7
0.0
7
0.4
49
γ-H
CH
(≥
LO
Q
vs
<
LO
Q)
0.0
6
−
0.0
5
0.1
8
0.2
81
(≥
LO
Q
vs
<
LO
Q)
0.0
6
−
0.0
5
0.1
8
0.2
81
(≥
LO
Q
vs
<
LO
Q)
0.0
6
−
0.0
6
0.1
8
0.2
97
He
pta
ch
lor
ep
ox
ide
(≥
LO
Q
vs
<
LO
Q)
0.0
5
−
0.1
3
0.2
3
0.5
98
(≥
LO
Q
vs
<
LO
Q)
0.0
5
−
0.1
3
0.2
3
0.5
98
(≥
LO
Q
vs
<
LO
Q)
0.0
5
−
0.1
4
0.2
3
0.6
21
Di
eld
rin
(≥
LO
Q
vs
<
LO
Q)
0.0
8
−
0.0
5
0.2
0
0.2
24
(≥
LO
Q
vs
<
LO
Q)
0.0
8
−
0.0
5
0.2
0
0.2
24
(≥
LO
Q
vs
<
LO
Q)
0.0
8
−
0.0
5
0.2
1
0.2
12
p,p
´-D
DE
(n
g/
mL
)
0.0
2
−
0.0
3
0.0
7
0.3
91
(n
g/
gl
ipi
d)
0.0
2
−
0.0
3
0.0
7
0.4
23
(n
g/
mL
)
0.0
2
−
0.0
3
0.0
7
0.4
24
o,p
´-D
DE
(≥
LO
Q
vs
<
LO
Q)
0.0
4
−
0.2
0
0.2
7
0.7
72
(≥
LO
Q
vs
<
LO
Q)
0.0
4
−
0.2
0
0.2
7
0.7
72
(≥
LO
Q
vs
<
LO
Q)
0.0
3
−
0.2
0
0.2
7
0.7
86
p,p
´-D
DT
(≥
LO
Q
vs
<
LO
Q)
0.0
4
−
0.1
5
0.2
3
0.6
85
(≥
LO
Q
vs
<
LO
Q)
0.0
4
−
0.1
5
0.2
3
0.6
85
(≥
LO
Q
vs
<
LO
Q)
0.0
5
−
0.1
6
0.2
6
0.6
19
PC
B-
28
(≥
LO
Q
vs
<
LO
Q)
−
0.2
3
−
0.6
7
0.2
1
0.3
09
(≥
LO
Q
vs
<
LO
Q)
−
0.2
3
−
0.6
7
0.2
1
0.3
09
(≥
LO
Q
vs
<
LO
Q)
−
0.2
4
−
0.6
8
0.2
1
0.2
97
PC
B-
52
(≥
LO
Q
vs
<
LO
Q)
−
0.0
6
−
0.3
3
0.2
1
0.6
63
(≥
LO
Q
vs
<
LO
Q)
−
0.0
6
−
0.3
3
0.2
1
0.6
63
(≥
LO
Q
vs
<
LO
Q)
−
0.0
7
−
0.3
4
0.2
0
0.6
15
PC
B-
10
1
(≥
LO
Q
vs
<
LO
Q)
−
0.1
0
−
0.2
2
0.0
2
0.1
12
(≥
LO
Q
vs
<
LO
Q)
−
0.1
0
−
0.2
2
0.0
2
0.1
12
(≥
LO
Q
vs
<
LO
Q)
−
0.1
0
−
0.2
3
0.0
2
0.1
03
PC
B-
13
8
(n
g/
mL
)
0.0
3
0.0
0
0.0
7
0.0
32
(n
g/
gl
ipi
d)
0.0
3
0.0
0
0.0
7
0.0
66
(n
g/
mL
)
0.0
3
0.0
0
0.0
7
0.0
32
PC
B-
15
3
(n
g/
mL
)
0.0
3
0.0
0
0.0
7
0.0
35
(n
g/
gl
ipi
d)
0.0
3
−
0.0
1
0.0
7
0.0
98
(n
g/
mL
)
0.0
3
0.0
0
0.0
7
0.0
35
PC
B-
18
0
(n
g/
mL
)
0.0
3
−
0.0
1
0.0
6
0.1
17
(n
g/
gl
ipi
d)
0.0
2
−
0.0
2
0.0
6
0.2
48
(n
g/
mL
)
0.0
3
−
0.0
1
0.0
6
0.1
17
Ca
dm
ium
(n
g/
mL
)
0.0
8
0.0
4
0.1
3
<
0.0
01
(n
g/
mL
)
0.0
8
0.0
4
0.1
3
<
0.0
01
(n
g/
mL
)
0.0
8
0.0
4
0.1
3
0.0
01
Le
ad
(n
g/
mL
)
0.0
1
−
0.0
2
0.0
4
0.5
63
(n
g/
mL
)
0.0
1
−
0.0
2
0.0
4
0.5
63
(n
g/
mL
)
0.0
1
−
0.0
2
0.0
5
0.5
36
CI
:c
on
fid
en
ce
int
erv
al;
Po
llu
tan
ta
nd
ur
ic
ac
id
co
nc
en
tra
tio
ns
we
re
log
-tr
an
sfo
rm
ed
.
Mo
de
ls
we
re
ad
jus
ted
for
sex
(m
ale
/fe
ma
le)
,a
ge
(y
rs)
,b
od
ym
as
si
nd
ex
(k
g/
m2
),
we
igh
tl
os
sd
ur
ing
th
el
as
t6
mo
nt
hs
(<
1K
g/
1–
5K
g/
≥
6K
g),
reg
ion
of
rec
ru
itm
en
t(
No
rth
,C
en
ter
,E
as
t,
So
ut
h)
,s
mo
kin
gh
ab
it
(n
on
-
sm
ok
er/
sm
ok
er/
for
me
rs
mo
ke
r),
alc
oh
ol
co
ns
um
pti
on
(n
on
-co
ns
um
er/
co
ns
um
er)
,e
du
ca
tio
n
(p
rim
ary
or
low
er/
sec
on
da
ry
/u
niv
ers
ity
);
Pla
ce
of
res
ide
nc
e(
cit
yc
en
ter
/o
th
er)
.
J.P. Arrebola et al. Environment International 123 (2019) 512–521
518
(Pollock et al., 2017). These variations in exposure levels might be
behind the discrepancies in different studies concerning their adverse
health effects and therefore, we believe that epidemiological studies
should address combined effects in populations from different geo-
graphical locations in order to elucidate the real effect of PTS mixtures.
In addition, several PTSs frequently show positive intra-family corre-
lations due to their similar physico-chemical properties (Artacho-
Cordon et al., 2015; Darrow et al., 2017), and this can lead to false-
positive findings as well as to an overestimation of the magnitude of the
associations when the effects are evaluated for individual chemicals. In
our study we used WQS analyses to ascertain potential mixture effects,
which pointed to a relevant effect of PCB-153 within the PCB mixtures
on the risk of hyperuricemia as well as on uric acid levels. In fact, those
BIOAMBIENT.ES participants showing ≥2 PTSs at increased con-
centrations experienced an higher risk of hyperuricemia. In comparison
to other approaches, WQS has been reported to have good sensitivity
and specificity when studying the mixture effect of environmental
pollutants, although its performance decreases when exposures are
highly correlated (Czarnota et al., 2015). We also need to consider that
underlying biological mechanisms are not considered in this models
and, hence, further confirmation in mechanistic studies would be of
interest.
There are large uncertainties regarding the potential mechanisms of
action of PTSs. Previous experimental studies have hypothesized that
certain pollutants might have an effect on uric acid homeostasis
through a disruption of antioxidant enzymes and subsequent generation
of reactive oxygen intermediates, that has been suggested for, e.g., Pb
(Kilikdar et al., 2011) or PFAs (Panaretakis et al., 2001). In addition, we
previously reported associations of chronic exposure to OCPs and PCBs
with the induction of alternative pathways to the glutathione detox-
ification route in humans, which might result in increased oxidative
stress (Artacho-Cordón et al., 2016). It is also possible that the observed
associations were a consequence of a PTS-induced chronic ne-
phrotoxicity through, for example, their interaction with anion trans-
porters involved in renal excretion (Kataria et al., 2015a). Indeed, ad-
verse renal outcomes have been linked to human exposure to Pb
(Sharma et al., 2013), PFAs, PAHs, and some PCBs, among others
(Kataria et al., 2015b). Furthermore, it has also been speculated that the
associations of PFAs with uric acid can be a consequence of a compe-
tition for the same renal transporters involved in the excretion of both
substances (Steenland et al., 2010). Though, adjustment for estimated
glomerular filtration rate did not change the previously-observed as-
sociations in the BIOAMBIENT.ES population (Supplemental Material,
Tables S3 and S4), which suggests the existence of additional me-
chanisms of action different than renal dysfunction, or at least not ac-
counted for by CDK-EPI.
The present study includes a relatively large study population with
residents from all Spanish regions, as well as a wide range of PTSs.
Additionally, the large amount of epidemiological and clinical data
collected in BIOAMBIENT.ES allowed us to adjust for most of the known
potential confounders. Despite the cross-sectional design, which limits
the assumption of a causal effect, the fact that we found associations of
PTS exposure with both prevalent hyperuricemia in the whole popu-
lation, as well as with uric acid levels in normouricemic participants,
reinforces the hypothesized role of PTS exposure in the disruption of
uric acid homeostasis, particularly in the case of PCBs −138
and− 153.
Another strength of this study is the adjustment for dietary habits,
which are acknowledged as major determinants of both PTS exposure as
well as hyperuricemia and, consequently, likely to confound the asso-
ciations. However, the inclusion of dietary covariates might cause
overadjustment, given that diet typically accounts for the majority of
PTS exposure (Arrebola et al., 2018) and, in this case, the direction of
the associations would be as follows: diet ➔ PTSs ➔ hyperuricemia.
Indeed, the magnitude association between PFOA and the risk of hy-
peruricemia considerably decreased after adjustment for dietary items.
In addition, this cross-sectional study might be prone to reversed-
causality, i.e., individuals diagnosed of hyperuricemia might have
modified their dietary habits and, therefore, their PTSs internal levels.
However, this would mainly affect the logistic regression models and
not so much the linear regression analyses (which included only in-
dividuals with no diagnosis of hyperuricemia). A similar issue also
applies to the models adjusting for glomerular filtration rate and fasting
glucose, which were performed to test if these comorbidities explained
the observed associations. However, these comorbidities might also
share common certain mechanisms of pathogenesis with hyperuricemia
(e.g. oxidative stress), and this might induce some degree of over-
adjustment in the analyses. Therefore, and even though the suggestive
increased number of significant associations found in these models, we
preferred to use a conservative approach and only assume those cor-
responding to the models with the lower level of adjustment. In relation
to serum lipids, several PTSs, e.g., OCPs and PCBs (Arrebola et al.,
2014) or Cadmium (Noor et al., 2018), have been suggested to disrupt
lipid homeostasis, which is closely related to hyperuricemia
(Jayashankar et al., 2016; Bonakdaran and Kharaqani, 2014; Peng
et al., 2015). Therefore, serum lipids might act as a confounder in the
models. However, serum lipids might also be mediator, a collider, part
of the causal pathway between SLs and hyperuricemia, or even a con-
sequence of a PTS-induced disruption of uric acid. For these reasons,
and considering the controversies regarding the need for considering
serum lipids when assessing potential health effects of PTSs (Porta
et al., 2009), we performed two sensitivity analyses, by entering the
Fig. 1. Estimation of the mixture effect of PCBs on the risk of hyperuricemia and uric acid levels using WQS.
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concentrations of lipophilic chemicals on a lipid basis, with and without
adjustment. The fact that we did not observe a relevant influence of
serum lipids in the associations might be related to the fasting condi-
tions in which the individuals were sampled, that would promote a
status of equilibrium across body compartments (Porta et al., 2009), or
simply because serum lipids are not relevant confounders in the asso-
ciations between PTSs and hyperuricemia. Our conceptual framework
for the adjustment for diet and serum lipids is presented as Supple-
mental Material, Fig. S1.
Furthermore, we cannot rule out the presence of undetected re-
sidual confounding that might bias the results and/or potential con-
founders not taken into account, e.g. physical exercise. In addition, we
cannot exclude potential chance findings related to multiple testing.
However, if we consider the most conservative results (non-adjusted for
diet, CDK-EPI or fasting glucose), our statistically significant associa-
tions in each model exceed the 5% that would be expected as a con-
sequence of chance findings using a p-value of 0.05. The risk of chance
findings is even higher in dichotomized variables (Bennette and
Vickers, 2012) and, therefore, our discussion is mostly focused on the
results with continuous predictors. Furthermore, in our opinion, even if
the reported associations were not considered true, their underlying
causes would be worth of further investigation since they might be a
proxy of other unknown external causes of the disease.
5. Conclusions
We found evidences of associations between human exposure to
mixtures of PTSs and disturbances in uric acid homeostasis, that ap-
peared to be independent of common sociodemographic and lifestyle
characteristics, dietary habits, glucose homeostasis and kidney func-
tion. However, we cannot rule out a potential residual confounding or
reversed-causality and further confirmation using longitudinal studies
is required.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.envint.2018.12.030.
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